HeartBeam (NASDAQ: BEAT) announced a strategic reorganization to accelerate execution, expand global market reach, and improve capital efficiency as it advances commercialization of its cardiac monitoring technology. Under the new structure, Founder and President Branislav Vajdic, Ph.D., and Executive Chairman Rich Ferrari will lead focused implementation teams designed to streamline decision-making, improve accountability, and reduce costs. As part of the transition, former CEO Robert Eno will move into a consulting role.
The company said its strategy centers on leveraging its patented 3D ECG platform across multiple healthcare channels while advancing development beyond arrhythmia assessment toward heart attack detection. HeartBeam also plans to expand partnerships with governments, health systems, ECG manufacturers, and wearable device companies, building on its December 2025 FDA clearance for its synthesized 12-lead ECG technology for arrhythmia assessment. The full press release is available at https://ibn.fm/CTxXi.
HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform is designed for portable devices that deliver actionable heart intelligence wherever the patient is. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility. The company’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. HeartBeam holds over 20 issued patents related to technology enablement.
The reorganization reflects a shift toward operational efficiency and partnership-driven growth. By concentrating authority in Vajdic and Ferrari, HeartBeam aims to reduce decision-making bottlenecks and accelerate time-to-market. The move also signals confidence in the company’s technology pipeline, particularly the expansion beyond arrhythmia monitoring into heart attack detection, which could address a major unmet need in cardiac care. Partnerships with governments and health systems may open new revenue streams and distribution channels globally.
The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT. Forward-looking statements in this article involve risks and uncertainties that could cause actual results to differ materially, as detailed in the company's SEC filings.
